The Rare Moments

See what’s been shared

Share Your Rare Moments

Your email address will not be published. Required fields are marked *

Disclaimer: Not all posts submitted will be able to be featured. If your post is selected, it will appear on the feed in February.

Comment is submitted and it is waiting for a review

Updated 2 months ago
Canary Advisors Canary Advisors Canary Advisors
The N=1 Collaborative The N=1 Collaborative

Connecting, Collaborating, Communicating, Challenges: Sharing experiences navigating family conversations in an n-of-1 investigational treatment setting. Learn more, below!

www.n1collaborative.org
Canary Advisors Canary Advisors Canary Advisors
Castleman Disease Collaborative Network Castleman Disease Collaborative Network Castleman Disease Collaborative Network

The Castleman Disease Collaborative Network (CDCN) is a global nonprofit organization dedicated to accelerating research and treatment for this rare and often deadly disease, supporting patients on their journeys, and revolutionizing biomedical research to cure countless other diseases. As we recognize Rare Disease Day on February 29, 2024, we are proud to share with you the story of one of the many thousands of Castleman disease patients who inspire our work every day. Learn more at cdcn.org.

www.youtube.com
Canary Advisors Canary Advisors Canary Advisors
Armelle Pindon Armelle Pindon Cure VCP

Happening now through 25 Feb – VCP International Conference!! Check out the abstracts from the many researchers who are participating in this meeting. By bridging the gaps between various disciplines, from oncology to neurodegeneration, the Cure VCP conference will drive innovation and coordination in research, accelerating our progress to find a cure for valosin-containing protein (VCP) associate multisystem proteinopathy (MSP).

www.curevcp.org
Amy Raymond Admin Amy Raymond Worldwide Clinical Trials

The Orphan Drug Act (ODA) of 1983 made the development of desperately needed new treatments for rare disease patient communities a possibility in ways it truly had not been before. Over the 40 years of the ODA, 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases. Additionally, 882 of those designations resulted in at least one FDA approval for use in 392 rare diseases. While having an approved treatment option for 5% of rare disease communities is progress, we’ve seen time and again how partnering with patient communities increases efficiency. Let’s all do more of that!

Daniel DeFabio Daniel DeFabio Global Genes

Fall of 2015, I attended my first rare disease advocacy conference. It was Global Genes Patient Advocacy Summit. I was overwhelmed and amazed at how many people were advocating for rare diseases and how many different paths they took. Meeting Bo Bigelow there certainly shaped my path. Although we faced different diagnoses (USP7 for his daughter Tess and Menkes Syndrome for my son Lucas), we had so much in common. Eventually we co-founded The Disorder Channel to stream rare disease films on TV. We collaborated with Global Genes to screen some of these films. And three years ago, I joined the staff at Global Genes to lead an online support community, to encourage others to share their #ZebraTales, to teach them rare disease filmmaking, and to help plan that same conference that started it all for me.

Zebra Tales

globalgenes.org
Peter Benton Admin Peter Benton Worldwide Clinical Trials

I’ve worked in this industry approaching 25 years. When I first started, most clinical trials focused on treating disease symptoms so patients could feel better and live fuller lives. Today, though, we’re treating the underlying pathophysiology of diseases, and we’ve only just begun to do amazing science. I’m proud of the work our global teams are doing in Precision Medicine and Personalized Medicines, hopefully leading to a brighter future for rare disease patients everywhere.

Jill Kiernan Jill Kiernan Tatton Brown Rahman Syndrome (TBRS)

This year for Rare Disease Day the Tatton Brown Rahman Syndrome (TBRS) Community is celebrating our many accomplishments from 2023! We are building on that momentum in 2024 with additional research into TBRS biomarkers and continuing to enroll samples into our TBRS biobank. Read more and celebrate with us here:

tbrsyndrome.org
LOAD MORE

We live for the rare moments.